Clinical Trials Browser

Phase 1 × Interventional × Renal Insufficiency × Clear all

NCT07154901 2026-05-22

Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)

Phase 1 Active not recruiting

34 enrolled

Lymphoid

Lymphoma, Follicular, Renal Insufficiency

NCT01366144 2026-04-13

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Phase 1 Active not recruiting

94 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Transitional Cell, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Unknown Primary, Ovarian Neoplasms, Testicular Neoplasms, Endometrial Neoplasms, Liver Failure, Renal Insufficiency

NCT06623630 2026-03-11

Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function

Phase 1 Recruiting

16 enrolled

Plasma cell

Multiple Myeloma, Renal Insufficiency

NCT04398745 2025-05-23

DREAMM12

Phase 1 Active not recruiting

36 enrolled

GenitourinaryPlasma cell

Kidney Failure, Chronic, Multiple Myeloma, Renal Insufficiency

Clinical Trials

Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function

DREAMM12

A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment

A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems

Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney Impairment

PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Renal Function

POM Renal

LVPK

Study of Copanlisib in Hepatic or Renal Impairment

Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD)

To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.

RENAL

Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction

A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment

BR in Patients With CLL With Comorbidities and/or Renal Dysfunction

A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function

A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function

Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment

Pharmacokinetics of LCZ696 in Subjects With Mild and Moderate Renal Impairment Compared to Healthy Subjects With Normal Renal Function

A Study on the Effect of Kidney Disease on a Diabetes Medication (0431-008)

To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects

Pharmacokinetics in Subjects With Renal Impairment

A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment

Safinamide Renal Impairment Trial

Combined Bone Marrow and Kidney Transplant for Multiple Myeloma With Kidney Failure

Oxaliplatin in Cancer Patients With Impaired Kidney Function